구조모아 (StructureMoa)항암 chemical structure spider web
방문Inotuzumab ozogamicin(Pfizer)은 Precursor Cell Lymphoblastic Leukemia-Ly 표적 ADC로, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 3 후기 임상 단계입니다. PFS: 5.0. PK: t½ 12.3 h. 차별점: unique toxicities related to the antigen target, linker, or payload that have limited their development.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Precursor Cell Lymphoblastic Leukemia-Ly
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia
Recruiting
2026-09-02
Data Confidence · Medium
Development Signal · Emerging
CAR-T Therapy and HSCT: A Case Series
linker, or payload that have limited their development
humanized anti‑cluster of differentiation (CD) 22 monoclonal antibody conjugated with calicheamicin th
unique toxicities related to the antigen target, linker, or payload that have limited their development
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
T-cell activation
payload that have limited their development
CD19 expression, whereas cytoplasmic CD22 expression
resistance to IO-induced apoptosis
구조화 데이터
xenograft (PDX) model
mouse
12.3
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Inotuzumab ozogamicin(Pfizer)은 Precursor Cell Lymphoblastic Leukemia-Ly 표적 ADC로, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 3 후기 임상 단계입니다. PFS: 5.0. PK: t½ 12.3 h. 차별점: unique toxicities related to the antigen target, linker, or payload that have limited their development.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
Precursor Cell Lymphoblastic Leukemia-Ly
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia
Recruiting
2026-09-02
Data Confidence · Medium
Development Signal · Emerging
CAR-T Therapy and HSCT: A Case Series
linker, or payload that have limited their development
humanized anti‑cluster of differentiation (CD) 22 monoclonal antibody conjugated with calicheamicin th
unique toxicities related to the antigen target, linker, or payload that have limited their development
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
T-cell activation
payload that have limited their development
CD19 expression, whereas cytoplasmic CD22 expression
resistance to IO-induced apoptosis
구조화 데이터
xenograft (PDX) model
mouse
12.3
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.